Search clinical trials for: ATB-1011

Total 5770 results

Autotelicbio

Recruiting

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Diabetes Mellitus, Type 2 | Essential Hypertension

Korea, Republic of
Cardix Therapeutics LLC

Not yet recruiting

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Bradycardia
Autotelicbio

Completed

Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

Healthy Adult Volunteers

Korea, Republic of
Brainvectis, a subsidiary of Asklepios BioPharmaceutical...

Active, not recruiting

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Huntington Disease

France
Benjamin Izar

Terminated

ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101)

Leiomyosarcoma | Liposarcoma

United States
Athira Pharma

Enrolling by invitation

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States, Australia
Athira Pharma
National Institute on Aging (NIA)

Completed

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease (ACT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States, Australia
Universidad de Granada

Completed

Clinical Study on the Use of Symbios Xenograft for Sinus Floor Elevation

Sinus Floor Augmentation

Spain
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Athira Pharma

Active, not recruiting

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Athira Pharma
Alturas Analytics, Inc.; Labcorp Drug Development Inc

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Healthy Volunteers

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People

Influenza

Hungary
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
Athira Pharma

Completed

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Dementia With Lewy Bodies | Parkinson Disease Dementia

United States
Damascus University

Completed

The Use of an Esthetic Twin Block for Patients With Mandibular Retrusion

Class II Malocclusion

Syrian Arab Republic
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Achieve Life Sciences

Completed

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada
AviadoBio Ltd

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) (ASPIRE-FTD)

Frontotemporal Dementia | FTD | FTD-GRN | Dementia, Frontotemporal

Netherlands, Spain, Poland, United States
Antengene Biologics Limited

Recruiting

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE)

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

United States, Australia
Millendo Therapeutics US, Inc.

Terminated

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Cushing Syndrome

United States, United Kingdom
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Completed

Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants

Dental Plaque

Canada
Kythera Biopharmaceuticals

Completed

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

Healthy

United States
Kythera Biopharmaceuticals

Completed

ATX-101 Abdominoplasty (ATX-101-08-10)

Characteristics of Subcutaneous Fat

United States
Kythera Biopharmaceuticals

Completed

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
Kythera Biopharmaceuticals

Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Healthy

United States
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
Millendo Therapeutics, Inc.

Completed

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Adrenocortical Carcinoma | Adrenal Cancer | ACC

United States, Germany
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Herantis Pharma Plc.

Terminated

A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema

Finland
Achieve Life Sciences

Unknown

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Taiwan, Spain, Israel, Italy, Korea, Republic of, New Zealand, Australia, Germany, United States, Hungary, Poland, Russian Federation, Singapore, Thailand, Ukraine
Antibe Therapeutics Inc.
Algorithme Pharma Inc

Completed

Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects

Chronic Pain

Canada
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Cumberland Pharmaceuticals

Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Pathologic Processes | Skin Diseases | Autoimmune Diseases | Connective Tissue Diseases | Scleroderma, Systemic | Scleroderma, Diffuse | Scleroderma, Limited | Sclerosis, Progressive Systemic

United States, India
Millendo Therapeutics, Inc.

Completed

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia

United States
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Healthy
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Cairo University

Completed

Effect of Ivabradine on Microcirculation and Cardiac Output in Septic Shock Patients

Septic Shock

Egypt
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Arsenal Biosciences, Inc.

Recruiting

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Neoplasms, Glandular and Epithelial | Recurrence | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Abdominal Neoplasm | Genital Neoplasm, Female

United States
The Christie NHS Foundation Trust

Completed

ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers (ABC-08)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer | Ampullary Cancer

United Kingdom
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia

Search clinical trials for: ATB-1011

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations